<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide has been linked to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) after autotransplants for <z:mp ids='MP_0009440'>myeloma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Total therapy trials (TT; TT2(-/+) thalidomide) and TT3 (TT3a with <z:chebi fb="0" ids="52717">bortezomib</z:chebi>, thalidomide; TT3b with additional lenalidomide) offered the opportunity to examine the contribution of these immune-modulatory agents to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-associated cytogenetic abnormalities (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-CA) and clinical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> ("clinical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/AL") </plain></SENT>
<SENT sid="2" pm="."><plain>Of 1080 patients with serial cytogenetic studies, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-CA occurred in 11% and clinical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/AL in 3% </plain></SENT>
<SENT sid="3" pm="."><plain>Risk features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-CA included TT3b, age ≥65 years, male gender, levels of β-2-microglobulin &gt;5.5 mg/L, and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> relapse </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/AL occurred less frequently in the control arm of TT2 and more often with TT3a and TT3b </plain></SENT>
<SENT sid="5" pm="."><plain>Since <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-CA often antedated clinical disease, periodic cytogenetic monitoring is recommended </plain></SENT>
<SENT sid="6" pm="."><plain>Larger CD34 quantities should be collected upfront as the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> could be reduced by applying higher CD34 doses with transplant </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, treatment, host, and <z:mp ids='MP_0009440'>myeloma</z:mp> features could be linked to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> development after therapy for this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>This trial was registered at www.clinicaltrials.gov: TT3A: NCT00081939, TT3B: NCT00572169 </plain></SENT>
</text></document>